Teva sues two Indian generics over Huntington’s treatment
06-07-2021
Teva, Mylan, Sandoz and Aurobindo hit with patent suit
02-12-2016
Postmodern Studio / Shutterstock.com
Israel-headquartered Teva has settled its dispute with Indian generic maker Aurobindo over a drug used to treat Huntington’s disease.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Teva Pharmaceuticals, Aurobindo, Lupin Pharmaceuticals, patent infringement, generics, Austedo, ANDA, settlement
